Characteristics of study subjects
| Characteristic . | All patients (N = 30) . | Responders (n = 11) . | Nonresponders (n = 19) . | P* . |
|---|---|---|---|---|
| Age, median (IQR), y | 61 (54-68) | 56 (51-58) | 65 (58-69) | .048 |
| Male sex | 16 (53) | 6 (55) | 10 (53) | >.99 |
| Hispanic or Latino | 12 (40) | 6 (55) | 6 (32) | .27 |
| Race | .58 | |||
| White | 24 (80) | 8 (73) | 16 (84) | |
| Black/African American | 5 (17) | 3 (27) | 2 (11) | |
| Asian | 1 (3) | 0 | 1 (5) | |
| Type of transplant | .02 | |||
| Allogeneic | 17 (57) | 3 (27) | 14 (74) | |
| Autologous | 13 (43) | 8 (73) | 5 (26) | |
| Stem cell source | .62 | |||
| Peripheral blood | 25 (83) | 10 (91) | 15 (79) | |
| Bone marrow | 5 (17) | 1 (9) | 4 (21) | |
| Immunosuppression at vaccine administration | ||||
| Any | 9 (30) | 3 (27) | 6 (32) | >.99 |
| Tacrolimus | 3 (10) | 1 (9) | 2 (11) | >.99 |
| Steroids† | 6 (20) | 1 (9) | 5 (26) | .37 |
| Dasatinib | 1 (3) | 1 (9) | 0 | .37 |
| ≥2 immunosuppressants at the time of vaccination | 3 (10) | 1 (9) | 2 (11) | >.99 |
| IVIG administration within 3 mo before vaccination or VZV IgG titer assessment | 3 (10) | 1 (9) | 2 (11) | >.99 |
| Type of donor‡ | >.99 | |||
| Unrelated | 12 (71) | 2 (67) | 10 (71) | |
| HLA-matched related | 5 (29) | 1 (33) | 4 (29) | |
| (D)onor/(R)ecipient CMV serostatus‡ | .58 | |||
| D-R+ | 5 (29) | 2 (67) | 3 (21) | |
| D+R+ | 8 (47) | 0 | 8 (57) | |
| D+R− | 2 (12) | 1 (33) | 1 (7) | |
| D+R− | 2 (12) | 0 | 2 (14) | |
| Time between transplant and vaccine first dose, median (IQR), mo | 8 (7-12) | 7 (6-10) | 10 (7-14) | .18 |
| Time between vaccine doses, median (IQR), d | 95 (59-138) | 116 (61-156) | 69 (59-128) | .45 |
| Time between completion of vaccine series and VZV IgG titers, median (IQR), mo | 4 (2-6) | 3 (2-6) | 5 (3-7) | .25 |
| CD34+ cells infused (1 × 106), median (IQR) | 4.8 (3.7-8.7) | 5 (3.7-8.2) | 4.6 (3.5-9) | .74 |
| ATG§ | 9 (30) | 2 (18) | 7 (37) | .42 |
| CD4+ T cells/µL, median (IQR)‡|| | 376 (255-442) | 242 (205-319) | 405 (284-475) | .08 |
| B cells/µL, median (IQR)*|| | 105 (33-218) | 101 (32-158) | 109 (25-230) | .69 |
| Conditioning regimen | .002 | |||
| Myeloablative | 15 (50) | 10 (91) | 5 (26) | |
| Reduced Intensity | 15 (50) | 1 (9) | 14 (74) | |
| Charlson Comorbidity Index, median (IQR) | 3 (2-3) | 3 (2-3) | 3 (2-3) | .62 |
| Main diagnosis | ||||
| Leukemia | 11 (37) | 1 (9) | 10 (53) | .02 |
| Lymphoma | 5 (17) | 1 (9) | 4 (21) | .63 |
| MDS/MPN | 2 (7) | 0 | 2 (11) | .52 |
| MM | 10 (33) | 8 (73) | 2 (11) | .001 |
| Other | 2 (6) | 1 (9) | 1 (5) | >.99 |
| Characteristic . | All patients (N = 30) . | Responders (n = 11) . | Nonresponders (n = 19) . | P* . |
|---|---|---|---|---|
| Age, median (IQR), y | 61 (54-68) | 56 (51-58) | 65 (58-69) | .048 |
| Male sex | 16 (53) | 6 (55) | 10 (53) | >.99 |
| Hispanic or Latino | 12 (40) | 6 (55) | 6 (32) | .27 |
| Race | .58 | |||
| White | 24 (80) | 8 (73) | 16 (84) | |
| Black/African American | 5 (17) | 3 (27) | 2 (11) | |
| Asian | 1 (3) | 0 | 1 (5) | |
| Type of transplant | .02 | |||
| Allogeneic | 17 (57) | 3 (27) | 14 (74) | |
| Autologous | 13 (43) | 8 (73) | 5 (26) | |
| Stem cell source | .62 | |||
| Peripheral blood | 25 (83) | 10 (91) | 15 (79) | |
| Bone marrow | 5 (17) | 1 (9) | 4 (21) | |
| Immunosuppression at vaccine administration | ||||
| Any | 9 (30) | 3 (27) | 6 (32) | >.99 |
| Tacrolimus | 3 (10) | 1 (9) | 2 (11) | >.99 |
| Steroids† | 6 (20) | 1 (9) | 5 (26) | .37 |
| Dasatinib | 1 (3) | 1 (9) | 0 | .37 |
| ≥2 immunosuppressants at the time of vaccination | 3 (10) | 1 (9) | 2 (11) | >.99 |
| IVIG administration within 3 mo before vaccination or VZV IgG titer assessment | 3 (10) | 1 (9) | 2 (11) | >.99 |
| Type of donor‡ | >.99 | |||
| Unrelated | 12 (71) | 2 (67) | 10 (71) | |
| HLA-matched related | 5 (29) | 1 (33) | 4 (29) | |
| (D)onor/(R)ecipient CMV serostatus‡ | .58 | |||
| D-R+ | 5 (29) | 2 (67) | 3 (21) | |
| D+R+ | 8 (47) | 0 | 8 (57) | |
| D+R− | 2 (12) | 1 (33) | 1 (7) | |
| D+R− | 2 (12) | 0 | 2 (14) | |
| Time between transplant and vaccine first dose, median (IQR), mo | 8 (7-12) | 7 (6-10) | 10 (7-14) | .18 |
| Time between vaccine doses, median (IQR), d | 95 (59-138) | 116 (61-156) | 69 (59-128) | .45 |
| Time between completion of vaccine series and VZV IgG titers, median (IQR), mo | 4 (2-6) | 3 (2-6) | 5 (3-7) | .25 |
| CD34+ cells infused (1 × 106), median (IQR) | 4.8 (3.7-8.7) | 5 (3.7-8.2) | 4.6 (3.5-9) | .74 |
| ATG§ | 9 (30) | 2 (18) | 7 (37) | .42 |
| CD4+ T cells/µL, median (IQR)‡|| | 376 (255-442) | 242 (205-319) | 405 (284-475) | .08 |
| B cells/µL, median (IQR)*|| | 105 (33-218) | 101 (32-158) | 109 (25-230) | .69 |
| Conditioning regimen | .002 | |||
| Myeloablative | 15 (50) | 10 (91) | 5 (26) | |
| Reduced Intensity | 15 (50) | 1 (9) | 14 (74) | |
| Charlson Comorbidity Index, median (IQR) | 3 (2-3) | 3 (2-3) | 3 (2-3) | .62 |
| Main diagnosis | ||||
| Leukemia | 11 (37) | 1 (9) | 10 (53) | .02 |
| Lymphoma | 5 (17) | 1 (9) | 4 (21) | .63 |
| MDS/MPN | 2 (7) | 0 | 2 (11) | .52 |
| MM | 10 (33) | 8 (73) | 2 (11) | .001 |
| Other | 2 (6) | 1 (9) | 1 (5) | >.99 |
Data are presented as absolute number (percentage), unless specified otherwise. Statistically significant P values (P < .05) are indicated in bold.
ATG, antithymocyte globulin; CMV, cytomegalovirus; IQR, interquartile range; IVIG, intravenous immunoglobulins; MDS/MPN, myelodysplastic syndrome/myeloproliferative neoplasm; MM, multiple myeloma.
P value for comparison between the responders and nonresponders groups by using Mann-Whitney U or Fisher’s exact test.
All the patients on steroids were receiving <0.5 mg/kg prednisone equivalent per day.
Data for 17 allogeneic transplant recipients.
Typical dose of ATG at our center is 4 mg/kg total.
Refers to cell counts in allogeneic HCT recipients before completion of vaccine series. Data missing for 1 patient.